BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rumsey DG, Myones B, Massicotte P. Diagnosis and treatment of antiphospholipid syndrome in childhood: A review. Blood Cells Mol Dis 2017;67:34-40. [PMID: 28283251 DOI: 10.1016/j.bcmd.2017.02.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Islabão AG, Trindade VC, da Mota LMH, Andrade DCO, Silva CA. Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. Paediatr Drugs 2021. [PMID: 34904182 DOI: 10.1007/s40272-021-00484-w] [Reference Citation Analysis]
2 Attilakos A, Fotis L, Dinopoulos A, Alexopoulos H, Theofilopoulou AV, Tzioufas AG, Mastroyianni S, Karalexi M, Garoufi A. Antiphospholipid and Antinuclear Antibodies in Children with Idiopathic Epilepsy: A 2-Year Prospective Study. J Clin Neurol 2020;16:140-4. [PMID: 31942770 DOI: 10.3988/jcn.2020.16.1.140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Ferriero DM, Fullerton HJ, Bernard TJ, Billinghurst L, Daniels SR, Debaun MR, deVeber G, Ichord RN, Jordan LC, Massicotte P, Meldau J, Roach ES, Smith ER; on behalf of the American Heart Association Stroke Council and Council on Cardiovascular and Stroke Nursing. Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke 2019;50. [DOI: 10.1161/str.0000000000000183] [Cited by in Crossref: 124] [Cited by in F6Publishing: 35] [Article Influence: 41.3] [Reference Citation Analysis]
4 Madison JA, Zuo Y, Knight JS. Pediatric antiphospholipid syndrome. Eur J Rheumatol. 2019;1-10. [PMID: 31804173 DOI: 10.5152/eurjrheum.2019.19160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
5 Madison JA, Gockman K, Hoy C, Tambralli A, Zuo Y, Knight JS. Pediatric antiphospholipid syndrome: clinical features and therapeutic interventions in a single center retrospective case series. Pediatr Rheumatol Online J 2022;20:17. [PMID: 35197077 DOI: 10.1186/s12969-022-00677-8] [Reference Citation Analysis]
6 Sloan E, Wright T, Zuo Y. Identifying additional risk factors for arterial and venous thrombosis among pediatric antiphospholipid antibodies carriers. Lupus 2021;30:828-32. [PMID: 33736541 DOI: 10.1177/09612033211002256] [Reference Citation Analysis]
7 Torres-jimenez A, Ramirez-nova V, Cespedes-cruz AI, Sanchez-jara B, Velazquez-cruz A, Bekker-méndez VC, Guerra-castillo FX. Primary antiphospholipid syndrome in pediatrics: beyond thrombosis. Report of 32 cases and review of the evidence. Pediatr Rheumatol 2022;20. [DOI: 10.1186/s12969-022-00673-y] [Reference Citation Analysis]
8 Brogna C, Luigetti M, Norcia G, Scalise R, Ferrantini G, Berti B, Romeo DM, Manna R, Mercuri E, Pane M. Pediatric Motor Inflammatory Neuropathy: The Role of Antiphospholipid Antibodies. Brain Sci 2020;10:E156. [PMID: 32156084 DOI: 10.3390/brainsci10030156] [Reference Citation Analysis]
9 Demir Yenigürbüz F, Ören H. Pediatric Deep Venous Thrombosis and Pulmonary Embolism: Can It Be Antiphospholipid Syndrome? Turk J Haematol 2019;36:205-6. [PMID: 30201599 DOI: 10.4274/tjh.galenos.2018.2018.0214] [Reference Citation Analysis]
10 Singer HS. Autoantibody-Associated Movement Disorders in Children: Proven and Proposed. Semin Pediatr Neurol 2017;24:168-79. [PMID: 29103424 DOI: 10.1016/j.spen.2017.08.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]